Patents by Inventor Leonard Lothstein

Leonard Lothstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
    Publication number: 20230255993
    Abstract: The present invention relates to compositions comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and methods for using the compositions in the treatment of triple negative breast cancer (TNBC) by administering an effective amount of the compositions to a subject. In some instances, the subject is a mammal, including at least one of human, feline, and canine mammals.
    Type: Application
    Filed: April 21, 2023
    Publication date: August 17, 2023
    Inventors: Leonard Lothstein, Judith Soberman, Tiffany N. Seagroves
  • Pivarubicin and benzarubicin compositions
    Patent number: 11666589
    Abstract: The present invention relates to compositions comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and methods for using the compositions in the treatment of triple negative breast cancer (TNBC) by administering an effective amount of the compositions to a subject. In some instances, the subject is a mammal, including at least one of human, feline, and canine mammals.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: June 6, 2023
    Inventors: Leonard Lothstein, Judith Soberman, Tiffany N. Seagroves
  • TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
    Publication number: 20210268007
    Abstract: The present invention relates to compositions comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and methods for using the compositions in the treatment of triple negative breast cancer (TNBC) by administering an effective amount of the compositions to a subject. In some instances, the subject is a mammal, including at least one of human, feline, and canine mammals.
    Type: Application
    Filed: March 2, 2021
    Publication date: September 2, 2021
    Inventors: Leonard Lothstein, Judith Soberman, Tiffany N. Seagroves
  • LIPOSOMES FOR HEMATOLOGICAL TUMORS
    Publication number: 20150071989
    Abstract: Targeted liposomes containing chemotherapeutic compounds of Formula (I) are provided for treating hematological cancers. The targeted liposomes can be targeted to cancer cells (e.g., malignant B cells) by attachment to an antibody or antibody fragment of a suitable cell surface antigen, e.g., CD22. The targeted liposomes have higher IC50s for cells not having the cell surface antigen as compared to similar non-targeted liposomes. Also provided are methods of preparing the targeted liposomes.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 12, 2015
    Inventors: Nivesh K. Mittal, George C. Wood, Leonard Lothstein, Pavan Balabathula, Bivash Mandal
  • Use of PKC-activating compounds as cardioprotectants and as apoptosis-inducing anti-tumor agents
    Patent number: 7541342
    Abstract: Compounds for the inducing apoptosis in cancer cells are described. The described compounds induce the translocation of protein kinase C-? to the mitochondria and the phosphorylation of mitochondrial phospholipid scramblase 3. The compounds also provide cardioprotection through the translocation and activation of protein kinase C-? in cardiomyocytes, thereby inhibiting apoptosis in carciomyocytes.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: June 2, 2009
    Assignee: University of Tennessee Research Foundation
    Inventors: Leonard Lothstein, Mervyn Israel, Trevor Sweatman, Polly A. Hofmann
  • Use of PKC-activating compounds as cardioprotectants and as apoptosis-inducing anti-tumor agents
    Publication number: 20060199775
    Abstract: Compounds for the inducing apoptosis in cancer cells are described. The described compounds induce the translocation of protein kinase C-? to the mitochondria and the phosphorylation of mitochondrial phospholipid scramblase 3. The compounds also provide cardioprotection through the translocation and activation of protein kinase C-? in cardiomyocytes, thereby inhibiting apoptosis in carciomyocytes.
    Type: Application
    Filed: March 6, 2006
    Publication date: September 7, 2006
    Inventors: Leonard Lothstein, Mervyn Israel, Trevor Sweatman, Polly Hofmann